Leptoprol (Leuprorelin)

Leuprorelin mimics natural GnRH and binds to pituitary GnRH receptors. After an initial hormone surge, it desensitizes the receptors, leading to sustained suppression of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This reduces gonadal steroid production, lowering testosterone or estrogen levels that drive the target diseases.

The specific dose and dosing schedule of Leptoprol are determined by the prescribing physician based on the patient’s condition, disease severity, and treatment goals. Dosage may vary for different indications and is adjusted during therapy as needed.

Leptoprol is contraindicated in pregnancy because it suppresses sex hormone production essential for fetal development. It is also not recommended during breastfeeding, as it may affect milk production and expose the infant to hormonal changes. Effective contraception is required for women of childbearing potential.

To request Leptoprol, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Leptoprol (leuprorelin) is a long‑acting GnRH agonist similar to leuprolide and goserelin. All provide sustained hormone suppression, but differences exist in dosing intervals, formulation stability and specific regulatory approvals. GnRH antagonists such as degarelix achieve rapid suppression without the initial hormone surge, which may be preferred in certain clinical scenarios.

Leptoprol should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Leptoprol is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a qualified healthcare professional using aseptic technique. The exact injection site, volume and frequency are prescribed by the treating physician according to the indication.

Serious risks include significant loss of bone mineral density leading to osteoporosis, severe allergic reactions such as anaphylaxis, and cardiovascular events in patients with pre‑existing heart disease. Patients should be monitored regularly for bone health, cardiovascular status and any signs of hypersensitivity.

Leptoprol should not be used by individuals who are pregnant, have known hypersensitivity to leuprorelin or any excipients, or have uncontrolled severe cardiovascular disease. Caution is also advised for patients with active liver disease or those receiving other hormonal therapies that could interfere with its action.